Health Care [ 4/12 ] | Biotechnology [ 20/74 ]
NASDAQ | Common Stock
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharmaB. V.
The company was founded in 2013 and is headquartered in Emeryville, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 25 | -0.86 Decreased by -30.30% | -0.86 Increased by +0.24% |
| Feb 26, 25 | -0.90 Decreased by -20.00% | -0.84 Decreased by -7.41% |
| Nov 7, 24 | -0.79 Decreased by -229.17% | -0.70 Decreased by -12.86% |
| Aug 8, 24 | -0.63 Increased by +18.18% | -0.70 Increased by +10.00% |
| May 9, 24 | -0.66 Increased by +25.00% | -0.74 Increased by +10.81% |
| Feb 29, 24 | -0.75 Increased by +10.71% | -0.74 Decreased by -1.35% |
| Nov 9, 23 | -0.24 Increased by +69.62% | -0.59 Increased by +59.32% |
| Aug 9, 23 | -0.77 Increased by +11.49% | -0.81 Increased by +4.94% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 14.00 K Decreased by -50.00% | -47.97 M Decreased by -48.06% | Decreased by -342.66 K% Decreased by -196.11% |
| Dec 31, 24 | 1.00 K Increased by +105.26% | -49.67 M Decreased by -53.86% | Decreased by -4.97 M% Decreased by -3.02 K% |
| Sep 30, 24 | 3.00 K Decreased by -99.99% | -43.84 M Decreased by -327.49% | Decreased by -1.46 M% Decreased by -2.88 M% |
| Jun 30, 24 | 5.00 K Decreased by -97.91% | -34.95 M Decreased by -18.02% | Decreased by -699.06 K% Decreased by -5.54 K% |
| Mar 31, 24 | 28.00 K Decreased by -90.60% | -32.40 M Decreased by -18.87% | Decreased by -115.72 K% Decreased by -1.17 K% |
| Dec 31, 23 | -19.00 K Decreased by -101.52% | -32.28 M Decreased by -18.37% | Increased by +169.91 K% Increased by +7.87 K% |
| Sep 30, 23 | 20.20 M Increased by +3.94 K% | -10.26 M Increased by +57.43% | Decreased by -50.76% Increased by +98.95% |
| Jun 30, 23 | 239.00 K Increased by +47.53% | -29.62 M Decreased by -8.06% | Decreased by -12.39 K% Increased by +26.75% |